Physician profile
Steven Leonowicz
NPI 1497378301
$1,540.02
in general payments reported to CMS, 2019-2025
16 companies · $796 in 2025
The $796 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $219 · 2022: $348 · 2023: $34.38 · 2024: $142 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $972.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $328.57 | 2022-2025 | |
| Novo Nordisk INC | $246.46 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $219.06 | 2021 | |
| Lilly USA, LLC | $121.20 | 2023-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $121.20 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Genzyme Corporation | $93.69 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.17 | 2024-2025 | Jardiance |
| Pfizer INC. | $81.56 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $70.60 | 2025 | Airsupra, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.71 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $30.04 | 2025 | Trelegy Ellipta |
| Tactile Systems Technology INC | $24.28 | 2025 | Nimbl, Flexitouch Plus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.35 | 2025 | Xifaxan |
| Amgen INC. | $19.67 | 2025 | Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $17.81 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $16.65 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Leonowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.